한국어
- Regulators on both sides of the Atlantic are putting specific numbers on estrogen and pharmaceutical residues, moving them from “emerging contaminant” to a verifiable spec.
- Conventional treatment leaves a measurable gap: clarification removes roughly 15% of micropollutants, while activated carbon filtration is the step that does most of the heavy lifting.
- Importers who can document removal of specific compounds now will hold a defensible specification when regulation tightens.
Municipal water filters were never designed to catch pharmaceuticals. They were built for sediment, chlorine, and a short list of regulated contaminants. That design gap is now showing up in procurement specs across the US and Europe, and it is changing what importers and distributors ask manufacturers for.
The regulatory signals are getting specific
For years, endocrine disruptors and pharmaceutical residues sat in the “emerging contaminant” bucket — real, but not urgent enough to write into a purchase order. That is changing. The US EPA’s Unregulated Contaminant Monitoring Rule (UCMR) has cycled through 136 constituents across five phases since 2000, and the agency has placed estradiol, estrone, and ethinyl estradiol on its evaluation list. On the European side, regulators have moved toward an annual mean target of 0.035 nanograms per litre for ethinyl estradiol — a concentration so low that only advanced treatment can reach it.
The scale of the problem is not trivial. Roughly a thousand endocrine-disrupting chemicals have been identified, and a 2024 systematic review of drinking water studies found sixteen estrogenic compounds, with the plasticizer DEHP detected at the highest concentration. The pattern is consistent: these compounds pass through conventional plants largely intact and reach the tap at trace levels that bioassays can still measure.
Conventional treatment leaves a measurable gap
Here is the uncomfortable number. Research on conventional treatment trains has found that clarification removes roughly 15% of micropollutants, disinfection about 32%, and activated carbon filtration about 53%. In other words, a large share of pharmaceutical and estrogenic compounds survives the standard process. Plants that still rely on coagulation, sedimentation, and chlorination are not a meaningful barrier to these contaminants.
This is not a theoretical concern. Studies of treated water have repeatedly detected caffeine, carbamazepine, bisphenol A, and hormonal compounds in public supply. The gap is real, and it is the gap that point-of-use and point-of-entry filtration is now being asked to close.
The technology stack that closes the gap
Three technologies do the heavy lifting, and they are not interchangeable.
| Technology | Mechanism | Removal capability | Watch-out |
|---|---|---|---|
| Activated carbon (GAC / block) | Adsorption | Median removal around 57%; biological activated carbon can exceed 99% for some trace organics | Capacity is finite; contact time and carbon spec decide performance |
| RO / nanofiltration membrane | Physical sieving + sorption | Captures hormones and BPA at the molecular level; RO removes dissolved salts and trace organics that pass carbon | Pressure and recovery ratio constrain residential installs |
| Ozonation | Oxidation | Around 90% of trace organics | Generates transformation products that can be more toxic than the parent; needs a carbon polish step |
The practical takeaway: no single stage wins. The workable configuration for micropollutant removal is carbon first, membrane second — the carbon extends membrane life and the membrane catches what carbon misses. Ozone is a municipal-scale tool, not a point-of-use one.
What this means for filter and OEM demand
For manufacturers and importers, the signal is that “removes pharmaceuticals” is moving from marketing language to a verifiable specification. Buyers are starting to ask the same question they once asked about lead and PFAS: which standard covers it, and can you prove it with a test. Filters that can document removal of specific compounds — with NSF/ANSI 42, 53, and 58 testing and third-party data — are separating from generic multi-stage claims.
The demand is not hypothetical. Municipal infrastructure degradation is already pushing point-of-use filtration into the mainstream, and the same ageing-pipe logic applies to trace organics: the closer water quality monitoring gets, the more downstream filtration becomes a requirement rather than a preference. Ageing municipal infrastructure is the demand driver, and micropollutant removal is its fastest-growing slice.
ONEMI’s position in this shift
ONEMI, a Guangdong-based water purification equipment manufacturer, builds the pieces this demand runs on: point-of-use RO systems, activated carbon blocks, and ultrafiltration stages that can be configured for micropollutant removal. The engineering question for OEM customers is not whether to add a stage, but which sequence delivers removal at a contact time and pressure that still works in a residential or light-commercial install. That is a media-selection and manufacturing problem, not a marketing one.
Getting it right comes down to the carbon specification — iodine number, mesh size, and bed contact time decide whether a carbon stage actually removes pharmaceuticals or just polishes taste. The differences between media types are the subject of carbon block media selection, and they matter more than most buyers assume. For OEM programs looking to build a defensible micropollutant position, the starting point is a manufacturing partner that can produce the full stack — carbon, membrane, and UF — under one roof. See the OEM factory capability page for how that production is structured.
Procurement takeaways
Three takeaways for importers and distributors.
First, ask for a test, not a claim. Request third-party removal data for the specific compounds your market cares about — a lab report naming carbamazepine or ethinyl estradiol is worth more than a paragraph about “99% of impurities.”
Second, watch the carbon spec. Iodine number, mesh size, and bed contact time determine whether a carbon stage actually removes pharmaceuticals or only masks taste and odour. Cheap carbon looks identical on a spec sheet and performs nowhere near it.
Third, treat this as a moat. The distributors who lock in verifiable micropollutant removal now are the ones holding a defensible specification when regulation tightens. The window to build that position is open today and will not stay open long.